• New growth engines: Symbiotec is leveraging its chemistry and fermentation biotechnology platform to expand into complex injectables specialty pharmaceuticals and large-scale fermentation-based CDMO.
• Debt reduction plan: After deploying over ₹800 crore in capex over the last 3 to 4 years, the company plans to use its ₹150 crore primary IPO proceeds to lower its net debt of approximately ₹380 crore.
• Steroid API capabilities: The company produces around 60 steroid hormone molecules, holds over 50 US DMFs and 25 European CEPs, and serves 250 global customers as India's only vertically integrated phytosterol-to-API manufacturer.
• Revenue diversification strategy: While top customers generate 40% to 50% of revenue due to high innovator demand, management expects the ₹800 to ₹850 crore capex into biopharmaceuticals and forward integration to significantly diversify revenue in the coming years.